Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non‐small‐cell lung cancer: A meta‐analysis of 15 phase II/III randomized trials

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|137|2|409-419

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.137, Iss.2, 2015-07, pp. : 409-419

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antiangiogenic Agents Combined with Chemotherapy in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Overall and Histology Subgroup-Specific Meta-Analysis

By  

Oncology Research and Treatment, Vol. 37, Iss. 12, 2014-11 ,pp. : 710-718

Karger

Access to resources Recommend Favorite

Paclitaxel, Carboplatin, and G-CSF in Advanced Non-Small-Cell Lung Cancer: A Phase I/II Study

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1998-09 ,pp. : 310-314

Karger

Access to resources Recommend Favorite

The role of meta-analysis in defining clinical practice in advanced non-small-cell lung cancer

By Di Maio Massimo  

Clinical Investigation, Vol. 3, Iss. 6, 2013-06 ,pp. : 523-530

Future Science

Access to resources Recommend Favorite

Vinorelbine-Based Regimens as Salvage Treatment in Patients with Advanced Non-Small Cell Lung Cancer: Two Parallel Multicenter Phase II Trials

By  

Oncology, Vol. 60, Iss. 3, 2001-04 ,pp. : 235-241

Karger

Access to resources Recommend Favorite

Preliminary Results of Combined Therapy with Topotecan and Carboplatin in Advanced Non-Small-Cell Lung Cancer

By  

Oncology, Vol. 61, Iss. 1, 2001-09 ,pp. : 47-54

Karger

Access to resources Recommend Favorite